Posts

CinRx and Graviton form CinRock to pursue ROCK2 therapies for heart and lung conditions

on
On Nov. 2, 2026, CinRx Pharma and Graviton BioScience announced CinRock Pharma, a jointly governed company to develop selective ROCK2-targeted therapies for cardiovascular disease. CinRock plans to advance two compounds originating with Graviton. The initial focus is pulmonary arterial hypertension (PAH), heart failure with preserved ejection fraction (HFpEF), and other cardiomyopathies; the companies say the candidates have properties supporting distribution to cardiac tissue. CinRx founder and CEO Jonathan Isaacsohn will lead CinRock and its research and development, working with Graviton founder and CEO Samuel D. Waksal. Graviton contributes ROCK2 expertise and intellectual property; CinRx contributes capital and development infrastructure. The proposed rationale is that ROCK2 inhibition may affect fibrosis, inflammation, and cardiac hypertrophy. The programs are still in development, and the announcement did not provide clinical results, trial timelines, or financial terms. ...

FDA partial hold on Bright Minds’ BMB-101 trial sends shares sharply lower

on

Karyopharm’s proposed Ayrmid deal is part of a Chapter 11 restructuring

on

Merck to sell U.S. CDMO business to Lonza

on

InventisBio reports Phase III psoriasis win for nomelcitinib

on

Eos reports preliminary PTC-2105 results in aged rats

on

Tiziana reports mixed-positive Phase 2a results for intranasal foralumab

on

FDA grants accelerated approval to Inovio’s VOCERYQ for rare HPV-related airway disease

on

Rare kidney disease: closing the gap between discovery and care

on

ETX101 shows promising early signals in Dravet syndrome

on

Sanofi rules out major restructuring as it prepares for Dupixent’s patent loss

on

FDA approves camizestrant combination for ESR1-mutated advanced breast cancer

on

Recent Alzheimer’s developments across France, Germany, Italy and Spain

on